Search

Your search keyword '"Poliero, L."' showing total 14 results

Search Constraints

Start Over You searched for: Author "Poliero, L." Remove constraint Author: "Poliero, L." Publisher elsevier bv Remove constraint Publisher: elsevier bv
14 results on '"Poliero, L."'

Search Results

1. 1951P Niraparib and irinotecan combination in ATM-mutated colorectal cancer

2. 461P Real-time PCR-based assessment of RAS/BRAF mutations in the plasma of metastatic colorectal cancer (mCRC) patients: A single institution experience

3. P-200 Bone metastases from colorectal cancer correlate with biological characteristics of primary tumors: A retrospective analysis from a single institution

4. P-190 A retrospective study of regorafenib versus trifluridine/tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: Multi-institution real-life clinical data

5. Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer

6. GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype

7. Synergistic activity between niraparib and chemotherapy in colorectal cancer: Molecular determinants from a preclinical model

8. Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience

9. Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS

10. Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data

11. AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)

12. Functional inhibition of TGF-β in colorectal cancer cells and its interaction with AXL receptor

13. Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four consensus molecular subtypes

14. Receptor tyrosine kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines

Catalog

Books, media, physical & digital resources